anti-melanoma mab fragments
Various (V09)Various (V09) compound in X4 Pharmaceuticals's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
biotech · WHIM Syndrome · Neutropenias · XFOR
X4 Pharmaceuticals
X4 Pharmaceuticals, Inc
X4 Pharmaceuticals drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
61 N Beacon St, Boston, Massachusetts 02134, US HQ
2014 Founded
81 Employees
Public company Type
XFOR · NYSE Ticker
Company details
- Status
- Public
- HQ
- 61 N Beacon St, Boston, Massachusetts 02134, US
- Founded
- 2014
- Employees
- 81
- Programs
- 11
- Drugs
- 6
- Patents
- 16
X4 Pharmaceuticals pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
X4 Pharmaceuticals drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to X4 Pharmaceuticals in public FDA and regional records.
-
Development asset linked to X4 Pharmaceuticals in public FDA and regional records.
-
mavorixafor
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: C-X-C chemokine receptor type 4.
- Target
- C-X-C chemokine receptor type 4
- Mechanism
- C-X-C chemokine receptor type 4 antagonist
-
Development asset linked to X4 Pharmaceuticals in public FDA and regional records.
-
Development asset linked to X4 Pharmaceuticals in public FDA and regional records.